Shield Therapeutics (LSE:STX) Price-to-Operating-Cash-Flow : (As of May. 01, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-05-01), Shield Therapeutics's share price is £0.0135. Shield Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.04. Hence, Shield Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Shield Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 9 years, Shield Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 1874.86. The lowest was 296.29. And the median was 1102.57.

LSE:STX's Price-to-Operating-Cash-Flow is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 17.63
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Shield Therapeutics's Cash Flow from Operations per share for the six months ended in Jun. 2023 was £-0.03. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.04.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -29.60% per year.

During the past 9 years, Shield Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 55.90% per year. The lowest was -29.60% per year. And the median was 9.30% per year.

Shield Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Shield Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Price-to-Operating-Cash-Flow Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

296.29

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Shield Therapeutics's Price-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Price-to-Operating-Cash-Flow falls into.

Shield Therapeutics Price-to-Operating-Cash-Flow Calculation

Shield Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.0135	/	-0.04
	=

Shield Therapeutics's Share Price of today is £0.0135.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shield Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.04.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Shield Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.